Saturday, November 23, 2024
HomeTagsIMiD

IMiD

Bristol Myers Squibb’s Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed...

Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Abecma® (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics